Jeff Ecsedy

Jeff Ecsedy

Company: Ikena Oncology

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers 1:30 pm

As the landscape of approaches targeting RAS mutated cancers continues to grow, there are a whole host of investigational inhibitors focused on targeting the RAS signaling pathway and the high value targets which exist within. Now more than ever, it is critical to understand the regulatory mechanisms downstream and upstream of RAS and consider the…Read more

day: Day One

Overcoming Therapeutic Resistance by Targeting Mutant-KRAS Transducers 12:00 pm

Inhibiting transducers synergistically of KRAS mediated oncogenic signalsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.